1. Home
  2. CTMX

as 09-17-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Founded: 2008 Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 349.6M IPO Year: 2015
Target Price: $5.13 AVG Volume (30 days): 2.4M
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 0.49 EPS Growth: 263.20
52 Week Low/High: $0.40 - $3.10 Next Earning Date: 11-06-2025
Revenue: $141,100,000 Revenue Growth: 18.01%
Revenue Growth (this year): -30.62% Revenue Growth (next year): -54.55%

CTMX Daily Stock ML Predictions

Share on Social Networks: